Related references
Note: Only part of the references are listed.Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study
Kimford J. Meador et al.
JAMA NEUROLOGY (2021)
Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy
Page B. Pennell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Declining malformation rates with changed antiepileptic drug prescribing An observational study
Torbjorn Tomson et al.
NEUROLOGY (2019)
Therapeutic levetiracetam monitoring during pregnancy: mind the gap
Maya Berlin et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2019)
Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy
Kimford J. Meador et al.
EPILEPSY & BEHAVIOR (2018)
Zonisamide serum concentrations during pregnancy
Arne Reimers et al.
EPILEPSY RESEARCH (2018)
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry
Torbjorn Tomson et al.
LANCET NEUROLOGY (2018)
Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age
Ashwin Karanam et al.
ANNALS OF NEUROLOGY (2018)
Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy
P. Emanuela Voinescu et al.
NEUROLOGY (2018)
Prevalence and incidence of epilepsy A systematic review and meta-analysis of international studies
Kirsten M. Fiest et al.
NEUROLOGY (2017)
Fetal antiepileptic drug exposure and cognitive outcomes
Rebecca L. Bromley et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2017)
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate
Rebecca L. Bromley et al.
NEUROLOGY (2016)
Carbamazepine clearance and seizure stability during pregnancy
Emily L. Johnson et al.
EPILEPSY & BEHAVIOR (2014)
In utero exposure to levetiracetam vs valproate Development and language at 3 years of age
R. Shallcross et al.
NEUROLOGY (2014)
Model-based lamotrigine clearance changes during pregnancy: clinical implication
Akshanth R. Polepally et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry
Dina Battino et al.
EPILEPSIA (2013)
Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy
T. L. Reisinger et al.
EPILEPSY & BEHAVIOR (2013)
Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study
Kimford J. Meador et al.
LANCET NEUROLOGY (2013)
Comparative safety of antiepileptic drugs during pregnancy
S. Hernandez-Diaz et al.
NEUROLOGY (2012)
Lamotrigine and its N2-glucuronide during pregnancy: The significance of renal clearance and estradiol
Arne Reimers et al.
EPILEPSY RESEARCH (2011)
Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design
Nagdeep Giri et al.
DRUG METABOLISM AND DISPOSITION (2009)
Up-Regulation of UDP-Glucuronosyltransferase (UGT) 1A4 by 17β-Estradiol: A Potential Mechanism of Increased Lamotrigine Elimination in Pregnancy
Huiqing Chen et al.
DRUG METABOLISM AND DISPOSITION (2009)
Pharmacokinetics of topiramate during pregnancy
Inger Ohman et al.
EPILEPSY RESEARCH (2009)
Serum concentration/dose ratio of levetiracetam before, during and after pregnancy
Andreas Austgulen Westin et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2008)
High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry
Murali Subramanian et al.
THERAPEUTIC DRUG MONITORING (2008)
Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency
P. B. Pennell et al.
NEUROLOGY (2008)
Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy
Jakob Christensen et al.
NEUROLOGY (2006)
Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach
GD Anderson
CLINICAL PHARMACOKINETICS (2005)
Share Paper
